Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.14 USD
Change Today 0.00 / 0.00%
Volume 5.4K
INSV On Other Exchanges
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

insite vision inc (INSV) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/10/14 - $0.36
52 Week Low
06/3/14 - $0.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSITE VISION INC (INSV)

insite vision inc (INSV) Related Bloomberg News

View More Bloomberg News

insite vision inc (INSV) Related Businessweek News

No Related Businessweek News Found

insite vision inc (INSV) Details

InSite Vision Incorporated, an ophthalmic product development company, engages in developing ophthalmic pharmaceutical products to address unmet eye care needs in the United States. The company develops its products based on its proprietary DuraSite drug delivery technology. It offers AzaSite, a macrolide antibiotic for the treatment of bacterial conjunctivitis; and Besivance, a fluoroquinolone antibiotic for the treatment of bacterial conjunctivitis. The products under development include BromSite, which has completed Phase III clinical trials for the treatment of post-operative inflammation, as well as the prevention of post-operative eye pain; DexaSite, which has completed Phase III clinical trials for the treatment of ocular inflammation; and AzaSite Plus, a fixed combination of azithromycin and dexamethasone that is in Phase III clinical trials for the treatment of ocular inflammation and infection. It is also developing DuraSite 2, a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing ophthalmic therapeutics; and ISV-101, a DuraSite formulation with low concentration of bromfenac that is used for the treatment of dry eye diseases. The company has collaborative, licensing, and service agreements with Pfizer and Pfizer Products, Inc.; Akorn, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. InSite Vision Incorporated was founded in 1986 and is based in Alameda, California.

29 Employees
Last Reported Date: 02/18/15
Founded in 1986

insite vision inc (INSV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $392.1K
Chief Financial Officer and Vice President
Total Annual Compensation: $274.8K
Vice President of Operations and Quality
Total Annual Compensation: $243.4K
Chief Medical Officer, Vice President of Clin...
Total Annual Compensation: $357.7K
Vice President of Development and Secretary
Total Annual Compensation: $298.7K
Compensation as of Fiscal Year 2014.

insite vision inc (INSV) Key Developments

InSite Vision Incorporated Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

InSite Vision Incorporated reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $3.4 million compared to $1.2 million for the same period in 2014. The increase in Revenue was due to a $3.0 million upfront license payment. Net loss was $0.8 million, or $0.01 per diluted share, compared to a net loss of $4.7 million, or $0.04 per diluted share, in 2014. Net loss was lower for the quarter ended March 31, 2015 primarily due to the upfront license payment from Nicox, lower interest expense due to the cancellation of the AzaSite Notes and higher legal and R&D expenses incurred in 2014. Loss from operations was $497,000 against $3,472,000 a year ago.

InSite Vision Incorporated Announces Amendments to the Certificate of Incorporation

InSite Vision Incorporated at its annual meeting of stockholders held on March 31, 2015, approved the amendments to Article IV of the company's restated certificate of incorporation to effect an increase the number of authorized shares of the company's common stock from 240,000,000 shares to 350,000,000 shares, effective from April 1, 2015. The company also approved the amendments to Article IV of the company's restated certificate of incorporation to effect a contingent reverse stock split of the company's issued and outstanding common stock.

Nicox Enters into Licensing Agreement with Insite Vision

Nicox S.A., has entered into a licensing agreement with InSite Vision Inc. to develop, manufacture and commercialize InSite's ophthalmic therapeutics, AzaSite, BromSite and AzaSite Xtra. All three products are based on InSite's proprietary Durasite drug delivery technology, which is designed to extend the duration of a drug in the eye. The agreement grants Nicox exclusive rights to all three products in Europe, Middle East and Africa. European Marketing Authorization Applications (MAAs) for AzaSite and BromSite are expected to be filed by First Quarter 2016, with the first launch expected in late 2017.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSV:US $0.14 USD 0.00

INSV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Johnson & Johnson $102.42 USD -1.18
Pfizer Inc $34.36 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation INSV Industry Range
Price/Earnings 0.6x
Price/Sales 1.8x
Price/Book NM Not Meaningful
Price/Cash Flow 0.6x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSITE VISION INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at